CN116332919A - ALK inhibitor compound and preparation method of intermediate thereof - Google Patents

ALK inhibitor compound and preparation method of intermediate thereof Download PDF

Info

Publication number
CN116332919A
CN116332919A CN202310323853.8A CN202310323853A CN116332919A CN 116332919 A CN116332919 A CN 116332919A CN 202310323853 A CN202310323853 A CN 202310323853A CN 116332919 A CN116332919 A CN 116332919A
Authority
CN
China
Prior art keywords
compound
solvent
reaction
molar ratio
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310323853.8A
Other languages
Chinese (zh)
Inventor
许峰
钱志维
吴天助
季风华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yasheng Pharmaceutical Group Hong Kong Co ltd
Suzhou Yasheng Pharmaceutical Co ltd
Original Assignee
Yasheng Pharmaceutical Group Hong Kong Co ltd
Suzhou Yasheng Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yasheng Pharmaceutical Group Hong Kong Co ltd, Suzhou Yasheng Pharmaceutical Co ltd filed Critical Yasheng Pharmaceutical Group Hong Kong Co ltd
Publication of CN116332919A publication Critical patent/CN116332919A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a preparation method of an ALK inhibitor compound and an intermediate thereof. Specifically, the invention discloses a preparation method of a compound A9, which comprises the following reaction steps: (1) In a solvent, in the presence of a metal catalyst and alkali, carrying out a coupling reaction on a compound A2 or salt thereof and a compound B3 or salt thereof to obtain a compound A4; (2) And (3) in a solvent, carrying out a coupling reaction on the compound A4 and the compound A8 in the presence of an organic acid to obtain a compound A9. The preparation method has the advantages of proper reaction steps, simple and convenient operation, cheap and easily obtained reaction raw materials, environmental friendliness, simple and convenient post-treatment, low safety risk, production period, reduced production cost and the like.

Description

ALK inhibitor compound and preparation method of intermediate thereof
Technical Field
The invention relates to a preparation method of ALK inhibitor compound and intermediate thereof.
Background
Anaplastic Lymphoma Kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in the development of hematopoietic and non-hematopoietic tumors. Aberrant expression of full-length ALK receptor proteins in renuroblastomas and glioblastomas has been reported; and ALK fusion proteins appear in anaplastic large cell lymphomas. Research on ALK fusion proteins also opens up new treatment possibilities for ALK positive malignancy patients. Small molecule ALK inhibitors have therapeutic potential for treating diseases and conditions in which ALK plays a role, including cancer.
The prior art discloses a preparation method of a compound A9 serving as an ALK inhibitor, and the preparation route is as follows:
Figure BDA0004152661160000011
the production cycle of the route is longer, the palladium catalyst is more in material consumption, the production cost is higher, and the synthetic route is complex.
Disclosure of Invention
The invention aims to solve the technical problems that the existing ALK inhibitor preparation method has longer production period, higher production cost and complex synthetic route, and provides the ALK inhibitor compound and the preparation method of the intermediate thereof.
The invention provides a preparation method of a compound A9, which comprises the following reaction steps: (1) In a solvent, in the presence of a metal catalyst and alkali, carrying out a coupling reaction on a compound A2 or salt thereof and a compound B3 or salt thereof to obtain a compound A4;
Figure BDA0004152661160000021
(2) In a solvent, carrying out coupling reaction on a compound A4 and a compound A8 in the presence of organic acid to obtain a compound A9;
Figure BDA0004152661160000022
X 1 OTf, cl, br or I;
X 2 and X 3 Each independently is H or C 1-6 An alkyl group; alternatively, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -。
In some embodiments, X 1 Is Br, i.e
Figure BDA0004152661160000023
Is->
Figure BDA0004152661160000024
In some embodiments, X 1 Is OTf, cl or I; cl is preferred.
In some embodiments, X 2 And X 3 Each independently is H or C 1-6 An alkyl group.
In some embodiments, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -, i.e
Figure BDA0004152661160000031
Is->
Figure BDA0004152661160000032
In some embodiments, in step (1), the solvent is one or more of an alcohol solvent, an ether solvent, an aromatic solvent, a nitrile solvent, a sulfoxide solvent, an amide solvent, and water, for example, a combination of an alcohol solvent and water, a combination of an ether solvent and water, an aromatic solvent, a nitrile solvent, a sulfoxide solvent, or an amide solvent.
In some embodiments, in step (1), the alcoholic solvent is isopropanol.
In some embodiments, in step (1), the ether-based solvent is dioxane and/or methyl ether.
In some embodiments, in step (1), the aromatic solvent is toluene.
In some embodiments, in step (1), the nitrile solvent is acetonitrile.
In some embodiments, in step (1), the sulfoxide solvent is dimethyl sulfoxide.
In some embodiments, in step (1), the amide-based solvent is N, N-dimethylformamide.
In some embodiments, in step (1), when the solvent is a combination of an alcoholic solvent and water, the volume ratio of the alcoholic solvent to the water is (4-20): 1, such as 4.5:1, 19.9:1, or 10.0:1.
In some embodiments, in step (1), the salt of compound A2 is the hydrochloride salt form of compound A2.
In some embodiments, in step (1), when the salt of compound A2 is the hydrochloride salt form of compound A2, the molar ratio of compound A2 to hydrochloric acid is 1:1.
In some embodiments, in step (1), the salt of compound B3 is the hydrochloride salt form of compound B3.
In some embodiments, in step (1), when the salt of compound B3 is in the hydrochloride form of compound B3, the molar ratio of compound B3 to hydrochloric acid is 1:1.
In some embodiments, in step (1), the metal catalyst is a palladium catalystFor example Pd (PPh) 3 ) 2 Cl 2 、Pd(dppf) 2 Cl 2 、Pd(OAc) 2 And Pd (PPh) 3 ) 4 Preferably Pd (PPh) 3 ) 4 And/or Pd (OAc) 2 The method comprises the steps of carrying out a first treatment on the surface of the More preferably Pd (PPh) 3 ) 4 。
In some embodiments, in step (1), the base is an alkali metal carbonate and/or an alkali metal phosphate, such as potassium carbonate and/or potassium phosphate; potassium carbonate is preferred.
In some embodiments, in step (1), the molar ratio of compound B3 to compound A2 is (1-1.1) to 1, such as 1.1: 1,1.05:1 or 1.0:1.
In some embodiments, in step (1), the molar ratio of the metal catalyst to the compound A2 is (0.01-0.02) to 1, e.g., 0.01:1 or 0.02:1.
In some embodiments, in step (1), the molar ratio of the base to the compound A2 is (3.0-5.0) to 1, e.g., 3.0: 1,4.0:1 or 5.0:1.
In some embodiments, in step (1), when the solvent is a combination of an alcoholic solvent and water, the molar ratio of water to the compound A2 is (9-24) to 1, such as 9:1 or 9.5:1.
In some embodiments, in step (1), the reaction temperature of the coupling reaction is 80 to 120 ℃, preferably 80 to 85 ℃.
In some embodiments, in step (1), the coupling reaction is performed under an inert gas blanket, such as nitrogen blanket.
In some embodiments, in step (1), the coupling reaction further comprises the following post-treatment steps: concentration (e.g., spin-drying), extraction (e.g., using ethyl acetate and 10% sodium carbonate solution), filtration, removal of metal catalyst (e.g., using N-acetyl-L-cysteine), concentration of filtrate (e.g., concentration under reduced pressure), washing (e.g., washing with 10% sodium carbonate solution), drying (e.g., drying with anhydrous magnesium sulfate), and recrystallization (e.g., recrystallization with N-heptane).
In some embodiments, in step (2), the solvent is an alcoholic solvent, such as isopropanol.
In some embodiments, in step (2), the organic acid is p-toluenesulfonic acid, e.g., p-toluenesulfonic acid monohydrate.
In some embodiments, in step (2), the molar ratio of said compound A8 to said compound A4 is (1-1.5) to 1, e.g. 1.05:1.
In some embodiments, in step (2), the molar ratio of the organic acid to the compound A4 is (1-1.5) to 1, e.g., 1.2:1.
In some embodiments, in step (2), the mass to volume ratio of the compound A4 to the solvent is 1g to (6-15) ml, e.g., 1g to 8ml.
In some embodiments, in step (2), the temperature of the coupling reaction is 70-90 ℃, preferably 77-83 ℃.
In some embodiments, in step (2), the coupling reaction is performed under an inert gas blanket, such as nitrogen blanket.
In some embodiments, in step (2), the coupling reaction further comprises the following post-treatment steps: crystallization (e.g., crystallization using ethyl acetate), filtration, washing (e.g., washing with 10% sodium carbonate solution after dissolution with methylene chloride), extraction (e.g., extraction of the aqueous phase with methylene chloride), concentration under reduced pressure, crystallization (e.g., crystallization using acetonitrile), and drying.
In some embodiments, the method of preparing compound A9 further comprises the steps of: in a solvent, under the action of a reducing agent, carrying out a reduction reaction on the compound A1 to obtain a compound A2 or a salt thereof;
Figure BDA0004152661160000051
in some embodiments, X 1 Is Br, i.e
Figure BDA0004152661160000052
Is->
Figure BDA0004152661160000053
Figure BDA0004152661160000054
Is that
Figure BDA0004152661160000055
In some embodiments, X 1 Is OTf, cl or I; cl is preferred.
In some embodiments, the reduction reaction is performed using an alcohol solvent and water.
In some embodiments, the alcoholic solvent is methanol in the reduction reaction.
In some embodiments, the volume ratio of the alcoholic solvent to the water in the reduction reaction is (5-20) to 1, e.g., 5:1.
In some embodiments, the salt of compound A2 is the hydrochloride salt form of compound A2.
In some embodiments, when the salt of compound A2 is the hydrochloride salt form of compound A2, the molar ratio of compound A2 to hydrochloric acid is 1:1.
In some embodiments, the mass to volume ratio of the compound A1 to the alcoholic solvent in the reduction reaction is 1g to (3-15) ml, for example 1g to 5ml.
In some embodiments, the reducing agent is SnCl in the reduction reaction 2 ·2H 2 O and HCl.
In some embodiments, the temperature of the reduction reaction is 45-55 ℃, e.g., 50 ℃.
In some embodiments, the molar ratio of the reducing agent to the compound A1 in the reduction reaction is (3-10) to 1, e.g., 4:1. When the reducing agent is SnCl 2 ·2H 2 O and HCl, the reducing agent is used in the molar ratio of the reducing agent to the compound A1 as SnCl 2 ·2H 2 O meter.
In some embodiments, the reduction reaction further comprises the following post-treatment steps: after addition of water, concentration (for example, after addition of water, concentration under reduced pressure), extraction (for example, extraction with methyl tert-butyl ether), washing (for example, washing with saturated brine), concentration, filtration and drying.
In some embodiments, when the hydrochloride salt form of compound A2 is obtained, the post-treatment step further comprises adding an acid (e.g., adding a 4M ethyl hydrogen chloride acetate solution).
In some embodiments, the method of preparing compound A9 further comprises the steps of: in a solvent, under the action of a reducing agent, carrying out reductive amination reaction on a compound B2 or salt thereof, tetrahydropyranone and acetic acid to obtain a compound B3 or salt thereof;
Figure BDA0004152661160000071
in some embodiments, X 2 And X 3 Each independently is H or C 1-6 An alkyl group.
In some embodiments, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -, i.e
Figure BDA0004152661160000072
Is->
Figure BDA0004152661160000073
Figure BDA0004152661160000074
Is that
Figure BDA0004152661160000075
In some embodiments, the solvent in the reductive amination reaction is a haloalkane solvent, such as dichloromethane.
In some embodiments, the salt of compound B2 is the hydrochloride salt form of compound B2.
In some embodiments, when the salt of compound B2 is the hydrochloride salt form of compound B2, the molar ratio of compound B2 to hydrochloric acid is 1:1.
In some embodiments, the salt of compound B3 is the hydrochloride salt form of compound B3.
In some embodiments, when the salt of compound B3 is the hydrochloride salt form of compound B3, the molar ratio of compound B3 to hydrochloric acid is 1:1.
In some embodiments, the reductive amination reaction wherein the reducing agent is sodium triacetoxyborohydride.
In some embodiments, the molar ratio of the tetrahydropyranone to the compound B2 in the reductive amination reaction is (2-5) to 1, for example 3:1.
In some embodiments, the molar ratio of acetic acid to compound B2 in the reductive amination reaction is (0.5-2) to 1, for example 0.85:1.
In some embodiments, the molar ratio of the reducing agent to the compound B2 in the reductive amination reaction is (2-5) to 1, e.g., 3:1.
In some embodiments, the mass to volume ratio of the compound B2 to the solvent in the reductive amination reaction is 1g to (5-20) ml, such as 1g to 10ml.
In some embodiments, the reductive amination reaction may also include the use of an organic acid, such as acetic acid.
In some embodiments, the reductive amination reaction further comprises the following post-treatment steps: extraction (e.g., with methylene chloride and 15% sodium carbonate solution), filtration (e.g., with celite), drying (e.g., with anhydrous magnesium sulfate), concentration (e.g., concentration under reduced pressure), and washing (e.g., washing with n-heptane).
In some embodiments, the temperature of the reductive amination reaction is room temperature.
In some embodiments, the method of preparing compound A9 further comprises the steps of: in a solvent, under an acidic condition, carrying out deprotection reaction on the compound B1 to obtain a compound B2 or a salt thereof;
Figure BDA0004152661160000081
X 4 is an amino protecting group; x is X 2 And X 3 Is defined as in any one of the present inventions.
In some embodiments, the amino protecting group is a group conventionally used in the art to protect an amino group, such as-Boc.
In some embodiments, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -, i.e
Figure BDA0004152661160000091
Is->
Figure BDA0004152661160000092
In some embodiments, X 2 And X 3 Each independently is H or C 1-6 An alkyl group.
In some embodiments of the present invention, in some embodiments,
Figure BDA0004152661160000093
is->
Figure BDA0004152661160000094
In some embodiments, the deprotection reaction, the solvent is an ester solvent, such as ethyl acetate.
In some embodiments, the salt of compound B2 is the hydrochloride salt form of compound B2.
In some embodiments, when the salt of compound B2 is the hydrochloride salt form of compound B2, the molar ratio of compound B2 to hydrochloric acid is 1:1.
In some embodiments, in the deprotection reaction, the acid in the acidic condition is hydrogen chloride. The hydrogen chloride may be added in the form of an ethyl acetate solution of hydrogen chloride. The concentration of the ethyl acetate solution of hydrogen chloride may be 4M.
In some embodiments, the deprotection reaction comprises a mass to volume ratio of the compound B1 to the solvent of 1g to (3-20) ml, e.g., 1g to 4.8ml.
In some embodiments, the molar ratio of the acid to the compound B1 in the deprotection reaction is (3-10) to 1, e.g., 6:1.
In some embodiments, the deprotection reaction is performed at room temperature.
In some embodiments, the deprotection reaction further comprises the following post-treatment steps: concentrating under reduced pressure, pulping (e.g., pulping with methyl tert-butyl ether), filtering, and drying.
The invention also provides a preparation method of the compound A4, which comprises the following reaction steps: in a solvent, in the presence of a metal catalyst and alkali, carrying out a coupling reaction on an A2 compound or salt thereof and a B3 compound or salt thereof to obtain a compound A4;
Figure BDA0004152661160000101
X 1 OTf, cl, br or I;
X 2 and X 3 Each independently is H or C 1-6 An alkyl group; alternatively, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -。
In some embodiments, X 1 Is Br, i.e
Figure BDA0004152661160000102
Is->
Figure BDA0004152661160000103
In some embodiments, X 1 Is OTf, cl or I; cl is preferred.
In some embodiments, X 2 And X 3 Each independently is H or C 1-6 An alkyl group.
In some embodiments, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -, i.e
Figure BDA0004152661160000104
Is->
Figure BDA0004152661160000105
In some embodiments, each step and reaction conditions in the process for the preparation of compound A4 are as described in any one of the preceding claims.
On the basis of conforming to the common knowledge in the field, the above preferred conditions can be arbitrarily combined to obtain the preferred examples of the invention.
The reagents and materials used in the present invention are commercially available.
The invention has the positive progress effects that: the preparation method has the advantages of proper reaction steps, simple and convenient operation, cheap and easily obtained reaction raw materials, environmental friendliness, simple and convenient post-treatment, low safety risk, production period, reduced production cost and the like.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Example 1
Figure BDA0004152661160000111
Stannous chloride dihydrate (65.86 g), methanol (100 ml), water (20 ml), concentrated hydrochloric acid (12 ml) and compound Al' (20.0 g) were sequentially added to a 1L reaction flask, heated to an internal temperature of 50℃and stirred for 4 hours, and the reaction was completed. The reaction system was cooled to room temperature, water (100 ml) was added, after concentrating under reduced pressure until the remaining about 100g, methyl tertiary ether (200 ml) was added and stirred, 20% sodium hydroxide solution was added dropwise to the aqueous phase ph=11 to 12, and the organic phase was collected as a liquid. The aqueous phase was back-extracted once with methyl tertiary ether (100 ml). The organic phases were combined and washed once with 15% sodium chloride solution (100 ml). The organic phase was concentrated to replace the solvent with ethyl acetate (100 ml x 2) to a residual of about 50g, 4M ethyl hydrogen chloride solution (70 ml) was added dropwise, stirred at room temperature for 1 hour, concentrated to replace with ethyl acetate (100 ml x 2) to a residual of about 100g, suction filtered and dried to give the A2' compound (18.05 g), purity 99.51%, yield 87%.
MS：[M+H]+＝244.0
1 H NMR(400MHz，DMSO-d6)δ7.37(s，1H)，7.28(s，1H)，4.78-4.67(m，1H)，2.26(d，J＝1.28Hz，3H)，1.29(dd，J＝6.04，1.31Hz，6H).
Example 2
Figure BDA0004152661160000121
To a 2L reaction flask, a compound of formula B1' (61.9 g) and ethyl acetate (300 ml) were successively added, and after the mixture was dissolved by stirring, a 4M ethyl acetate solution (300 ml) of hydrogen chloride was added dropwise at room temperature, followed by stirring for 2 hours, whereby the reaction was completed. The reaction mixture was concentrated to dryness under reduced pressure, methyl t-butyl ether (200 ml) was added thereto, and the mixture was slurried at room temperature for 2 hours, suction filtration and drying to give the compound of formula B2' (48.81 g), purity 97.9%, yield 99%.
1 H NMR(400MHz，DMSO-d6)δ9.29(s，2H)，6.36(td，J＝3.10，1.53Hz，1H)，3.58(dp，J＝5.08，2.47Hz，2H)，3.13-3.03(m，2H)，2.28(tq，J＝4.66，2.15Hz，2H)，1.22(s，12H).
Example 3
Figure BDA0004152661160000122
To a 2L reaction flask were successively added a compound of formula B2' (36.13 g), methylene chloride (360 ml), tetrahydropyranone (51.58 g) and acetic acid (8.84 g), and after stirring and purging, sodium triacetoxyborohydride (109.17 g) was added in portions, and the mixture was stirred at room temperature for 2.5 hours, whereby the reaction was completed. Dichloromethane (360 ml) was added to the system, 15% sodium carbonate solution (900 ml) was slowly added, 20% sodium hydroxide solution (150 ml) was added, the pH was adjusted to about 10 to 11, the mixture was filtered through celite, and the organic phase was collected. The aqueous phase was back extracted three times with dichloromethane (360 ml x 3). The organic phases were combined, dried over anhydrous magnesium sulfate, suction filtered, spin dried, ethyl acetate was added, concentrated under reduced pressure to constant weight, n-heptane (90 g) was added dropwise at room temperature, cooled to 0-5 ℃, stirred for 2 hours, suction filtered, dried compound of formula B3' (32.52 g), purity 99.68%, yield 75%.
1 H NMR(400MHz，Chloroform-d)δ6.53(tt，J＝3.52，1.87Hz，1H)，4.11-3.97(m，2H)，3.40(td，J＝11.88，1.99Hz，2H)，3.20(q，J＝3.03Hz，2H)，2.64(t，J＝5.62Hz，2H)，2.53(tt，J＝11.57，3.89Hz，1H)，2.34-2.25(m，2H)，1.81(ddd，J＝12.50，4.19，2.09Hz，2H)，1.64(qd，J＝12.18，4.51Hz，2H)，1.26(s，12H).
Example 4
Figure BDA0004152661160000131
To the reaction flask, compound A2 '(20.0 g), compound B3' (20.09 g), isopropyl alcohol (230 ml), water (11.55 g) and potassium carbonate (39.41 g) were sequentially added, stirring was started, nitrogen was replaced three times, tetrakis triphenylphosphine palladium (0.8237 g) was added, nitrogen was replaced three times, and the temperature was raised to 80 to 85 ℃ under nitrogen protection, stirring was performed for 24 hours, and the reaction was completed. The reaction system was cooled to 50-55℃and N-acetyl-L-cysteine (1.16 g) was added thereto, followed by stirring for 1 hour and cooling to room temperature. The system was concentrated to about 130g remaining, displaced twice with ethyl acetate (100 ml x 2) to about 130g remaining, ethyl acetate (200 ml) was added, washed once with 10% sodium carbonate solution (200 ml), suction filtered and the filtrate was collected. The filtrate was separated, N-acetyl-L-cysteine (1.16 g) was added to the organic phase, the temperature was raised to 50 to 55℃and stirred for 1 hour, cooled to room temperature, and washed once with 10% sodium carbonate solution (150 ml). N-acetyl-L-cysteine (1.16 g) was added to the organic phase, warmed to 50-55℃and stirred for 1 hour, cooled to room temperature and washed once with 10% sodium carbonate solution (150 ml). The organic phase is concentrated under reduced pressure until about 60g remains, methyl tertiary butyl ether (40 g) is added dropwise, n-heptane (100 g) is added dropwise at 20-25 ℃, after stirring for 30 minutes, the mixture is concentrated under reduced pressure until about 100g remains, n-heptane (100 g) is continuously added, the mixture is concentrated under reduced pressure until about 100g remains, the temperature is reduced to 0-5 ℃, stirring is carried out for 4 hours, suction filtration is carried out, and compound A4 (20.22 g) is obtained after drying, the purity is 97.6%, and the yield is 86%.
MS：[M+H]+＝331.20
1 H NMR(400MHz，DMSO-d6)δ6.49(s，1H)，6.44(s，1H)，5.42(dq，J＝3.54，1.65Hz，1H)，4.47(s，2H)，4.38(h，J＝6.05Hz，1H)，3.95-3.86(m，2H)，3.13(q，J＝2.95Hz，2H)，2.66(t，J＝5.51Hz，2H)，2.46(dt，J＝11.17，3.71Hz，1H)，2.23(dq，J＝6.10，3.43，2.92Hz，2H)，2.07(s，3H)，1.75(ddd，J＝12.26，4.11，1.98Hz，2H)，1.46(qd，J＝12.16，4.44Hz，2H)，1.23(d，J＝6.01Hz，6H).
Example 5
With reference to the synthetic method of the compound of example 4, the reaction parameters were optimized and adjusted to obtain the following results.
Figure BDA0004152661160000141
Example 6
Figure BDA0004152661160000142
To the reaction flask was successively added isopropanol (120 ml), A4 (15.0 g), A8 (16.5 g), p-toluenesulfonic acid monohydrate (10.36 g), stirred, and replaced with nitrogen three times. Heating to 80+/-3 ℃ under the protection of nitrogen, stirring and reacting for 24 hours, and finishing the reaction. Cooling to 60-65 ℃, dropwise adding ethyl acetate (120 ml), slowly cooling to 15+/-5 ℃, stirring for 2 hours, and carrying out suction filtration. The filter cake was dissolved in dichloromethane (90 m 1) with stirring, washed twice with 10% aqueous sodium carbonate (75 ml x 2). The aqueous phases were combined and extracted once with dichloromethane (45 ml). The organic phases were combined, concentrated under reduced pressure to a residual weight of about 37.5g, acetonitrile (75 ml) was added dropwise, concentrated under reduced pressure to a residual weight of about 67.5g, acetonitrile (75 ml) was added dropwise at a controlled temperature of 30.+ -. 10 ℃, cooled to 20.+ -. 5 ℃, stirred for 6 hours, and suction filtered. Oven-dried to give compound A9 (23.0 g), purity 99.74%, yield 79%.
MS：[M+H] + ＝640.10
1 H NMR(400MHz，Chloroform-d)δ9.51(s，1H)，8.59(dd，J＝8.41，1.08Hz，1H)，8.18(s，1H)，8.05(s，1H)，7.95(dd，J＝8.00，1.63Hz，1H)，7.65(ddd，J＝8.60，7.38，1.67Hz，1H)，7.60(s，1H)，6.72(s，1H)，5.59(dt，J＝3.64，1.96Hz，1H)，4.55(hept，J＝6.17Hz，1H)，4.09(dd，J＝11.28，4.24Hz，2H)，3.45(td，J＝11.88，1.93Hz，2H)，3.36-3.21(m，3H)，2.80(t，J＝5.56Hz，2H)，2.43(s，2H)，2.14(s，3H)，1.88(d，J＝12.42Hz，2H)，1.78-1.69(m，2H)，1.36(dd，J＝17.08，6.47Hz，13H)。

Claims (17)

1. A process for the preparation of compound A9 comprising the following reaction steps:
(1) In a solvent, in the presence of a metal catalyst and alkali, carrying out a coupling reaction on a compound A2 or salt thereof and a compound B3 or salt thereof to obtain a compound A4;
Figure FDA0004152661150000011
(2) In a solvent, carrying out coupling reaction on a compound A4 and a compound A8 in the presence of organic acid to obtain a compound A9;
Figure FDA0004152661150000012
X 1 OTf, cl, br or I;
X 2 and X 3 Each independently is H or C 1-6 An alkyl group; alternatively, X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -。
2. The process for the preparation of compound A9 according to claim 1, wherein said process satisfies one or more of the following conditions:
(1)X 1 is Br, i.e
Figure FDA0004152661150000013
Is->
Figure FDA0004152661150000014
(2)X 2 And X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -, i.e
Figure FDA0004152661150000021
Is->
Figure FDA0004152661150000022
3. The process for the preparation of compound A9 according to claim 1, wherein said process satisfies one or more of the following conditions:
(1)X 1 is OTf, cl or I; preferably Cl;
(2)X 2 and X 3 Each independently is H or C 1-6 An alkyl group.
4. A process for the preparation of compound A9 according to any one of claims 1 to 3, wherein the process meets one or more of the following conditions:
(1) In the step (1), the solvent is one or more of alcohol solvents, ether solvents, aromatic solvents, nitrile solvents, sulfoxide solvents, amide solvents and water;
(2) In step (1), the salt of compound A2 is the hydrochloride salt form of compound A2;
(3) In step (1), the salt of compound B3 is the hydrochloride salt form of compound B3;
(4) In the step (1), the metal catalyst is a palladium catalyst;
(5) In the step (1), the alkali is carbonate of alkali metal and/or phosphate of alkali metal;
(6) In the step (1), the molar ratio of the compound B3 to the compound A2 is (1-1.1) to 1;
(7) In the step (1), the molar ratio of the metal catalyst to the compound A2 is (0.01-0.02) to 1;
(8) In the step (1), the molar ratio of the alkali to the compound A2 is (3.0-5.0) to 1;
(9) In the step (1), when the solvent is a combination of an alcohol solvent and water, the molar ratio of the water to the compound A2 is (9-24) to 1;
(10) In the step (1), the reaction temperature of the coupling reaction is 80-120 ℃;
(11) In the step (1), the coupling reaction is carried out under the protection of inert gas;
(12) In step (1), the coupling reaction further comprises the following post-treatment steps: concentrating, extracting, filtering, removing metal catalyst, concentrating filtrate, washing, drying and recrystallizing;
(13) In the step (2), the solvent is an alcohol solvent;
(14) In the step (2), the organic acid is p-toluenesulfonic acid;
(15) In the step (2), the molar ratio of the compound A8 to the compound A4 is (1-1.5) to 1;
(16) In the step (2), the molar ratio of the organic acid to the compound A4 is (1-1.5) to 1;
(17) In the step (2), the mass volume ratio of the compound A4 to the solvent is 1g to (6-15) ml;
(18) In the step (2), the temperature of the coupling reaction is 70-90 ℃;
(19) In the step (2), the coupling reaction is carried out under the protection of inert gas;
(20) In step (2), the coupling reaction further comprises the following post-treatment steps: crystallization, filtration, washing, extraction, reduced pressure concentration, crystallization and drying.
5. The process for producing compound A9 according to claim 4, wherein one or more of the following conditions are satisfied:
(1) In the step (1), the solvent is a combination of an alcohol solvent and water, a combination of an ether solvent and water, an aromatic solvent, a nitrile solvent, a sulfoxide solvent or an amide solvent;
(2) In the step (1), when the solvent is a combination of an alcohol solvent and water, the volume ratio of the alcohol solvent to the water is (4-20) to 1;
(3) In the step (1), the alcohol solvent is isopropanol;
(4) In the step (1), the ether solvent is dioxane and/or methyl ether;
(5) In the step (1), the aromatic solvent is toluene;
(6) In the step (1), the nitrile solvent is acetonitrile;
(7) In the step (1), the sulfoxide solvent is dimethyl sulfoxide;
(8) In the step (1), the amide solvent is N, N-dimethylformamide;
(9) In the step (1), when the solvent is a combination of an alcohol solvent and water, the volume ratio of the alcohol solvent to the water is 4.5:1, 19.9:1 or 10.0:1;
(10) In the step (1), when the salt of the compound A2 is in the hydrochloride form of the compound A2, the molar ratio of the compound A2 to the hydrochloric acid is 1:1;
(11) In the step (1), when the salt of the compound B3 is in the hydrochloride form of the compound B3, the molar ratio of the compound B3 to the hydrochloric acid is 1:1;
(12) In the step (1), the metal catalyst is Pd (PPh) 3 ) 2 Cl 2 、Pd(dppf) 2 Cl 2 、Pd(OAc) 2 And Pd (PPh) 3 ) 4 Preferably Pd (PPh) 3 ) 4 And/or Pd (OAc) 2 The method comprises the steps of carrying out a first treatment on the surface of the More preferably Pd (PPh) 3 ) 4 ；
(13) In the step (1), the alkali is potassium carbonate and/or potassium phosphate; preferably potassium carbonate;
(14) In step (1), the molar ratio of the compound B3 to the compound A2 is 1.1: 1,1.05:1 or 1.0:1;
(15) In step (1), the molar ratio of the metal catalyst to the compound A2 is 0.01:1 or 0.02:1;
(16) In step (1), the molar ratio of the base to the compound A2 is 3.0: 1,4.0:1 or 5.0:1;
(17) In the step (1), when the solvent is a combination of an alcohol solvent and water, the molar ratio of the water to the compound A2 is 9:1 or 9.5:1;
(18) In the step (1), the reaction temperature of the coupling reaction is 80-85 ℃;
(19) In the step (1), the coupling reaction is carried out under the protection of nitrogen;
(20) In the step (2), the solvent is isopropanol;
(21) In step (2), the organic acid is p-toluenesulfonic acid monohydrate;
(22) In the step (2), the molar ratio of the compound A8 to the compound A4 is 1.05:1;
(23) In step (2), the molar ratio of the organic acid to the compound A4 is 1.2:1;
(24) In the step (2), the mass-volume ratio of the compound A4 to the solvent is 1g to 8ml;
(25) In the step (2), the temperature of the coupling reaction is 77-83 ℃;
(26) In the step (2), the coupling reaction is carried out under the protection of nitrogen.
6. A process for the preparation of compound A9 according to any one of claims 1 to 3, characterized in that in step (1) it further comprises the steps of: in a solvent, under the action of a reducing agent, carrying out a reduction reaction on the compound A1 to obtain a compound A2 or a salt thereof;
Figure FDA0004152661150000051
X 1 is defined as in any one of claims 1 to 3.
7. The method of preparing compound A9 according to claim 6, wherein the method of preparing satisfies one or more of the following conditions:
(1) In the reduction reaction, the solvent is an alcohol solvent and water;
(2) The salt of the compound A2 is in the hydrochloride form of the compound A2;
(3) In the reduction reaction, the mass volume ratio of the compound A1 to the alcohol solvent is 1g to (3-15) ml;
(4) In the reduction reaction, the reducing agent is SnCl 2 ·2H 2 O and HCl;
(5) The temperature of the reduction reaction is 45-55 ℃;
(6) In the reduction reaction, the mol ratio of the reducing agent to the compound A1 is (3-10) to 1; when the reducing agent is SnCl 2 ·2H 2 O and HCl, the reducing agent is used in the molar ratio of the reducing agent to the compound A1 as SnCl 2 ·2H 2 An O meter;
(7) The reduction reaction further comprises the following post-treatment steps: adding water, concentrating, extracting, washing, concentrating, filtering, and drying.
8. The process for producing compound A9 according to claim 7, wherein one or more of the following conditions are satisfied
(1) In the reduction reaction, the alcohol solvent is methanol;
(2) In the reduction reaction, the volume ratio of the alcohol solvent to the water is (5-20) to 1; for example 5:1;
(3) When the salt of the compound A2 is in the hydrochloride form of the compound A2, the molar ratio of the compound A2 to the hydrochloric acid is 1:1;
(4) In the reduction reaction, the mass volume ratio of the compound A1 to the alcohol solvent is 1g to 5ml;
(5) The temperature of the reduction reaction is 50 ℃;
(6) In the reduction reaction, the molar ratio of the reducing agent to the compound A1 is 4:1;
(7) When the hydrochloride form of compound A2 is obtained, the post-treatment step further comprises the addition of an acid.
9. A process for the preparation of compound A9 according to any one of claims 1 to 3, characterized in that in step (1) it further comprises the steps of: in a solvent, under the action of a reducing agent, carrying out reductive amination reaction on a compound B2 or salt thereof, tetrahydropyranone and acetic acid to obtain a compound B3 or salt thereof;
Figure FDA0004152661150000061
X 2 and X 3 Is defined as in any one of claims 1 to 3.
10. The method of preparing compound A9 of claim 9, wherein the method of preparing satisfies one or more of the following conditions:
(1) In the reductive amination reaction, the solvent is halogenated hydrocarbon solvent;
(2) The salt of the compound B2 is in the hydrochloride form of the compound B2;
(3) The salt of the compound B3 is in the hydrochloride form of the compound B3;
(4) In the reductive amination reaction, the reducing agent is sodium triacetoxyborohydride;
(5) In the reductive amination reaction, the molar ratio of the tetrahydropyranone to the compound B2 is (2-5) to 1;
(6) In the reductive amination reaction, the molar ratio of the acetic acid to the compound B2 is (0.5-2) to 1;
(7) In the reductive amination reaction, the mol ratio of the reducing agent to the compound B2 is (2-5) to 1;
(8) In the reductive amination reaction, the mass volume ratio of the compound B2 to the solvent is 1g to (5-20) ml;
(9) The reductive amination reaction may also include the use of organic acids;
(10) The reductive amination reaction further comprises the following post-treatment steps: extracting, filtering, drying, concentrating and washing;
(11) The temperature of the reductive amination reaction is room temperature.
11. The method of preparing compound A9 of claim 10, wherein the method of preparing satisfies one or more of the following conditions:
(1) In the reductive amination reaction, the solvent is dichloromethane;
(2) When the salt of the compound B2 is in the hydrochloride form of the compound B2, the molar ratio of the compound B2 to the hydrochloric acid is 1:1;
(3) When the salt of the compound B3 is in the hydrochloride form of the compound B3, the molar ratio of the compound B3 to the hydrochloric acid is 1:1;
(4) In the reductive amination reaction, the molar ratio of the tetrahydropyranone to the compound B2 is 3:1;
(5) In the reductive amination reaction, the molar ratio of the acetic acid to the compound B2 is 0.85:1;
(6) In the reductive amination reaction, the mol ratio of the reducing agent to the compound B2 is 3:1;
(7) In the reductive amination reaction, the mass volume ratio of the compound B2 to the solvent is 1g to 10ml;
(8) The organic acid is acetic acid.
12. The method for producing compound A9 according to claim 9, wherein in step (1), further comprising the steps of: in a solvent, under an acidic condition, carrying out deprotection reaction on the compound B1 to obtain a compound B2 or a salt thereof;
Figure FDA0004152661150000081
X 4 is an amino protecting group; x is X 2 And X 3 Is defined as set forth in claim 9.
13. The method of preparing compound A9 of claim 12, wherein the method of preparing satisfies one or more of the following conditions:
(1) The amino protecting group is-Boc;
(2)X 2 and X 3 Connection formation-C (CH) 3 ) 2 -C(CH 3 ) 2 -, i.e
Figure FDA0004152661150000082
Is->
Figure FDA0004152661150000083
14. The process for preparing compound A9 according to claim 12, wherein the process satisfies the following conditions:
X 2 and X 3 Each independently is H or C 1-6 An alkyl group.
15. The process for the preparation of compound A9 according to any one of claims 12 to 14, wherein said process satisfies one or more of the following conditions:
(1) In the deprotection reaction, the solvent is an ester solvent;
(2) The salt of the compound B2 is in the hydrochloride form of the compound B2;
(3) In the deprotection reaction, the acid in the acidic condition is hydrogen chloride;
(4) In the deprotection reaction, the mass volume ratio of the compound B1 to the solvent is 1g to (3-20) ml;
(5) In the deprotection reaction, the molar ratio of the acid to the compound B1 is (3-10) to 1;
(6) The deprotection reaction is carried out at room temperature;
(7) The deprotection reaction further comprises the following post-treatment steps: concentrating under reduced pressure, pulping, filtering, and drying.
16. The method of preparing compound A9 of claim 15, wherein the method of preparing satisfies one or more of the following conditions:
(1) In the deprotection reaction, the solvent is ethyl acetate;
(2) When the salt of the compound B2 is in the hydrochloride form of the compound B2, the molar ratio of the compound B2 to the hydrochloric acid is 1:1;
(3) The hydrogen chloride is added in the form of ethyl acetate solution of hydrogen chloride;
(4) When the hydrogen chloride is added in the form of an ethyl acetate solution of hydrogen chloride, the concentration of the ethyl acetate solution of hydrogen chloride is 4M;
(5) In the deprotection reaction, the mass volume ratio of the compound B1 to the solvent is 1g to 4.8ml;
(6) In the deprotection reaction, the molar ratio of the acid to the compound B1 is 6:1.
17. A process for the preparation of compound A4 comprising the following reaction steps: in a solvent, in the presence of a metal catalyst and alkali, carrying out a coupling reaction on an A2 compound or salt thereof and a B3 compound or salt thereof to obtain a compound A4;
Figure FDA0004152661150000091
wherein X is 1 、X 2 And X 3 And the steps and reaction conditions are as described in step (1) of any one of claims 1 to 16.
CN202310323853.8A 2022-03-30 2023-03-29 ALK inhibitor compound and preparation method of intermediate thereof Pending CN116332919A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022103322711 2022-03-30
CN202210332271 2022-03-30

Publications (1)

Publication Number Publication Date
CN116332919A true CN116332919A (en) 2023-06-27

Family

ID=86878546

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310323853.8A Pending CN116332919A (en) 2022-03-30 2023-03-29 ALK inhibitor compound and preparation method of intermediate thereof

Country Status (1)

Country Link
CN (1) CN116332919A (en)

Similar Documents

Publication Publication Date Title
US20230212184A1 (en) Thienopyrimidine derivatives and production methods thereof
CN104159898B (en) For the preparation of the method for the fluoro-1H-pyrazolo-pyridines of 5-replacing
CN101993407B (en) Indoline compound for preparing silodosin and preparation method thereof
US7799916B2 (en) Process for the preparation of 5-(4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl)benzofuran-2-carboxamide
EP2411373A1 (en) Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
CN114805314B (en) Synthesis method of Entecavir
CN112851646B (en) Preparation method of tergolian prazan
WO2009048864A1 (en) Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use
WO2006018955A1 (en) Process for the production of isoindole derivatives
CN116332919A (en) ALK inhibitor compound and preparation method of intermediate thereof
EP3081554B1 (en) Method for preparing silodosin and intermediate thereof
TWI762527B (en) Processes for preparing tph1 inhibitors
TW202302538A (en) Method for preparing intermediate for synthesizing sphingosine-1-phosphate receptor agonist
KR101012134B1 (en) Process for preparing imatinib or mesylate thereof
EP3848361A1 (en) Method of producing tetracyclic compound
CN103896889B (en) Lapatinib intermediate and its preparation method and application
CN113583003A (en) Vardenafil analogue and synthetic method and application thereof
JP2003504364A (en) Benzofuran derivative
CN113620869B (en) Preparation method of betrixaban
US8815870B2 (en) 4-(2-(6-substituted-hexylidene) hydrazinyl)benzonitrile and preparation thereof
CN112390816B (en) Preparation method of oxazepine compound
JP5711669B2 (en) Method for producing spiroketal derivative
JP5611207B2 (en) Stereoselective preparation of bicyclic heterocycles
CN117903111A (en) Preparation method of key intermediate of rui Lu Geli
TW202313600A (en) Preparation method of hepatitis B virus nucleocapsid inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination